Geneoscopy

Executive Summary

Geneoscopy is a privately held diagnostics company specializing in noninvasive, molecular-based tests for gastrointestinal health, leveraging its proprietary stool-derived eukaryotic RNA (seRNA) platform. Its lead product, ColoSense, is an FDA-approved colorectal cancer screening test that offers a convenient stool-based alternative to colonoscopy, addressing a significant unmet need in cancer prevention. The company's technology differentiates through the analysis of eukaryotic RNA, potentially improving sensitivity for detecting precancerous lesions. With colorectal cancer being the second leading cause of cancer death in the US, Geneoscopy targets a large and growing market. The company is positioned to compete with existing stool-based tests like Exact Sciences' Cologuard, but with a novel biomarker approach. As a private firm with limited public data, its valuation and financials are undisclosed, yet its FDA approval provides a strong foundation for commercialization and potential partnerships.

Upcoming Catalysts (preview)

• Q3 2026Commercial Launch and Reimbursement Expansion for ColoSense70% success
• Q4 2026Publication of Additional Clinical Validation Data60% success
• Q2 2027Partnership with Major Healthcare Systems or Diagnostic Distributors50% success